LEXINGTON, Mass., April 2, 2012 (GLOBE NEWSWIRE) -- Agenus Inc. (Nasdaq:AGEN) reported today that Dr. Andrew Parsa, Professor in Residence, Department of Neurological Surgery, University of California San Francisco (UCSF), will present an abstract entitled, “A Phase 2 multicenter trial of autologous heat shock protein-peptide vaccine (HSPPC-96; vitespen) for recurrent glioblastoma multiforme (GBM) patients shows improved survival compared to a contemporary cohort controlled for age, KPS and extent of resection,” at the 80th American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in Miami, Florida, April 14-18, 2012. Dr. Parsa’s presentation will be given during Plenary Session II of the AANS meeting, which is scheduled for April 17, 2012 at 10:30 am ET.
